InDevR partners with bioMérieux

InDevR, Inc., a provider of analytical technologies for vaccines and biotherapeutics, has announced that it has raised $9 million in series B financing. Adjuvant Capital has invested $4 million, and bioMérieux, a worldwide leader in in vitro diagnostics and microbiological quality control solutions for the food and pharmaceutical industries, has raised $5 million. Together, these investments will support InDevR’s commercial expansion and ongoing development of new reagent kits for its VaxArray® platform. bioMérieux will also become the exclusive distributor of the VaxArray portfolio in Europe.

VaxArray is based on a versatile and multiplexed microarray technology, with specific recognition and quantification of antigens, antibodies or nucleic acids, including mRNA. This technology complements bioMérieux’s expertise in applying immunoassays to vaccine production, as Michael Reynier, Senior Vice President of pharma quality control at bioMérieux, explained, “We quickly recognized the high quality of InDevR's products and team, and realized that we share a common vision and mindset. This partnership reflects our desire to expand our offerings with high value-added solutions for pharmaceutical companies.”

Glenn Rockman, managing partner at Adjuvant Capital, commented, “InDevR has already successfully developed critical quality attribute (CQA)/QC tools for pneumococcus, polio, measles and rubella vaccines, as well as for mRNA vaccines. We have been impressed with InDevR’s efficiency and dedication, and we are delighted to continue supporting the company alongside the experienced team at bioMérieux.”

VaxArray has also recently proven to be an excellent solution for mRNA CQA/QC testing, providing high specificity and sensitivity while eliminating the need for extracting mRNA from lipid nanoparticles. Kathy Rowlen, CEO at InDevR, said, “We are on a mission to revolutionize CQA/QC testing for vaccines and therapeutics. VaxArray provides us with the means to align the rapid advancement of mRNA vaccines and cell and gene therapies with more efficient, standardized and cost-effective analytical tools. The partnership with bioMérieux accelerates our efforts to achieve this goal.”

Want the latest science news straight to your inbox?Become a SelectScience member for free today >>